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ABSTRACT   
 
High naevus count is the strongest risk factor for melanoma and although gene 
variants have been discovered for both traits, epigenetic variation is unexplored. We 
investigated 322 healthy human skin DNA methylomes associated with total body 
naevi count, incorporating genetic and transcriptomic variation.  
DNA methylation changes were identified at genes involved in melanocyte 
biology, such as RAF1 (p = 1.2 x 10-6) and CTC1 (region: p = 6.3 x 10-4), and other 
genes including ARRDC1 (p = 3.1 x 10-7). A subset exhibited coordinated methylation 
and transcription changes within the same biopsy. The total analysis was also 
enriched for melanoma-associated DNA methylation variation (p = 6.33 x 10-6). 
Additionally, we show that skin DNA methylation is associated in cis with known 
GWAS SNPs for naevus count, at PLA2G6 (p = 1.7 x 10-49) and NID1 (p = 6.4 x 10-
14), as well as melanoma risk, including in or near MC1R, MX2 and TERT/CLPTM1L 
(p < 1 x 10-10). 
Our analysis using a uniquely large dataset comprising healthy skin DNA 
methylomes identified known and additional regulatory loci and pathways in naevi 
and melanoma biology. This integrative study improves our understanding of 
predisposition to naevi and their potential contribution to melanoma pathogenesis. 
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INTRODUCTION  
 
The total body number of melanocytic naevi is the strongest risk and 
predictive factor for melanoma in Caucasian populations (Gandini et al. 2005; Olsen 
et al. 2009). Melanoma is the most aggressive of skin tumours with an increasing 
incidence (Siegel et al. 2014). These malignancies arise from an existing benign 
naevus in 20% to 50% of cases (Haenssle HA et al. 2016; Purdue et al. 2005; Shitara 
et al. 2014; Weatherhead et al. 2007). The vast majority of naevi never progress to 
melanoma, however naevi count is still a predisposition marker for melanoma arising 
de novo (Chang et al. 2009). Therefore, further understanding of the biology of naevi 
will give insights into the development and pathology of melanoma.  
Typically, the number of naevi decrease after the age of 40, however, in 
individuals at high risk of melanoma, this loss of naevi is delayed, reflecting an 
altered senescence (Newton et al. 1993). Furthermore, a higher total body naevus 
count has also been associated with longer telomere length in blood in individuals 
from the TwinsUK cohort (Bataille et al. 2007). This link with senescence may 
indicate that the total numbers of naevi reflect differences in senescence pathways 
between individuals that can be detected in skin tissue where naevi are found. The 
usefulness of naevus counts as an intermediate phenotype to melanoma has already 
been shown in genome-wide association studies (GWAS), as common single 
nucleotide polymorphisms (SNPs) in the loci PLA2G6 and MTAP were first 
associated with total body naevus count (Falchi et al. 2009; Nan et al. 2011) and then 
subsequently with melanoma risk (Barrett et al. 2011; Bishop et al. 2009). For naevus 
count, variants in PLA2G6 were replicated across two studies that also identified 
additional associations in NID1, c11orf74, and MTAP. Though GWAS have identified 
genetic variation for naevi count and melanoma, the variance in naevus counts 
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explained by these genes is low and no study has previously examined epigenetic 
variation in this context.  
Here, we explore epigenome-wide DNA methylation variation in healthy 
human skin tissue in relation to total body naevus counts in 322 female individuals 
from the TwinsUK cohort. The focus of this study is on the potential to identify a 
predisposing DNA methylation signature of normal skin to the number of naevi and 
not the malignant changes occurring in melanocytes themselves. It has become 
increasingly acknowledged that cross talk between all cells within the skin and 
melanocytes is important in the progression to melanoma (Kaur et al. 2016; Kim et al. 
2013; Li et al. 2003; Shih et al. 1994). We investigated individual CpG differentially 
methylated positions (DMPs), as well as differentially methylated regions (DMRs) in 
healthy skin tissue, and corresponding gene expression changes within the same 
tissue. To study the potential interaction between genetic variants and DNA 
methylation, we examined the association between the skin DNA methylome and 
genetic variants previously associated with naevus count or melanoma risk by 
GWAS.  
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RESULTS 
 
The skin DNA methylome and its tissue layer specificity 
 
As expected, due to the differing cell types in skin within the dermis and 
epidermis, these tissue layers harbour distinct DNA methylation profiles (Vandiver et 
al. 2015). In our study, skin tissue DNA was derived from a peri-umbilical punch 
biopsy (adipose tissue was removed from the biopsy before freezing) from 322 
healthy female twins and profiled using the Infinium HumanMethylation450 
BeadChip. To confirm which skin layer was represented in our biopsy sample, we 
compared our DNA methylation dataset to recently published DNA methylation 
profiles of mechanically separated epidermal (36 individuals) and dermal tissue (36 
individuals) from Vandiver et al. (Vandiver et al. 2015). Principal component analysis 
(PCA) was performed on unadjusted DNA methylation profiles of the three groups of 
samples (dermis (n=40), epidermis (n=38), and our whole skin sample (n=322)). The 
first two principal components (PCs) explain 55.6% of the variance, capturing the 
skin layer specificity of the dermis and epidermis samples as previously shown 
(Vandiver et al. 2015). Our whole skin DNA methylation profiles cluster closely with 
the dermal layer DNA methylation profiles (Figure 1).   
 
 
Single CpG site differential skin DNA methylation in relation to total body 
naevus count  
 We first explored evidence for differential skin DNA methylation associated 
with total body naevus count at the single CpG-site level across the genome in 322 
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healthy female twins. We fitted a linear mixed effects model regressing DNA 
methylation levels on fixed effects (age, BMI, smoking status, chip, order on the chip, 
and bisulphite conversion efficiency) and random effects (family structure and 
zygosity). Three differentially methylated positions were identified to be significantly 
associated with total body naevus count (n-DMPs) at a false discovery rate (FDR) of 
5% and a further 45 associations were observed at a FDR of 10% (Figure 2 A, Table 
1, Table S1). The 48 n-DMPs are enriched for strong enhancers (ChromHMM state 4) 
in the NHEK cell line derived from epidermal keratinocytes (p = 0.03) and for CpG 
island (CGI) shores  (2kb either side of the CGI, p = 0.04), while depleted for signals 
located in open sea genomic regions that are more than 4kb beyond CGIs (p = 2.2 x 
10-3).  
 The strongest signals are shown Table 1 and Figure 2 B. The most associated 
signal (cg06244240, p = 5.5 x 10-8) lies in a CGI shore ~6.5kb downstream of 
METRNL, which is expressed in skin (Ushach et al. 2015) and is also involved in 
neural cell formation. The second ranked signal (cg06123942, p = 2.2 x 10-7) is in the 
5’ CGI promoter of C15orf48, that displays reduced expression in squamous cell 
carcinoma (Freiberger et al. 2015). The third ranked signal (cg25384157, p = 3.1 x 10-
7) is positively associated with the number of naevi and is in a CGI shore ~1.5kb 
upstream of the transcription start site (TSS) of ARRDC1, a negative regulator of the 
Notch signalling pathway (Puca et al. 2013). The CpG (cg11297934, p = 1.2 x 10-6) 
lies ~200 bp upstream of the TSS of proto-oncogene RAF1 (also known as CRAF), 
which is a member of the RAF family in the ERK/MAPK pathway that includes the 
key player BRAF.  
Six out of our top 10 n-DMPs did not show direct association with age (p = 
0.05) including two of the top four results (ARRDC1 and RAF1), with no n-DMP 
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associations with age surpassing FDR 10% correction (Figure 2 C). The remaining 
four signals did not show stronger evidence for association with age alone compared 
to naevus count. These results suggest that the majority of top-ranked n-DMPs are not 
directly associated with age.  
 
Regional differential skin DNA methylation associated with total body naevus 
count  
 We next aimed to identify differentially methylated regions, that is, small 
genomic regions that contain multiple CpG sites and show consistent directional 
association with total body naevus count (n-DMRs). DMRs have been found in 
general to be enriched for functionally relevant regions as well as for GWAS SNPs 
from the GWAS catalogue (Ziller et al. 2013). We applied the BumpHunter (Jaffe et 
al. 2012) algorithm and identified 48 n-DMRs (p < 0.01) genome-wide (Table 2, 
Table S2).  
 Subsequently, we examined the genomic context of the n-DMRs. The 
strongest signal (p = 6.8 x 10-5, Figure 3 A) was observed overlapping the 5’ CGI 
promoter of ARRDC1. This n-DMR includes the third ranked FDR 5% individual 
CpG n-DMP (cg25384157). We also identified an n-DMR in CTC1 that shows 
consistent negative association with total body naevus count amongst its three CpG 
sites (Figure 3 B). It is in a region with active promoter evidence across multiple 
ENCODE cell types including NHEK, that resides in the 3’ UTR of CTC1 but also 
2kb upstream of the lincRNA LINC00324. CTC1 is a component of the CTS complex 
that has a pivotal role in protecting telomeres from degradation.  
 
Naevus differential methylation signatures reflected in gene expression changes 
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 We then explored individual CpG sites in the 48 n-DMRs for association with 
gene expression levels using transcription profiles available in 248 individuals using 
the same skin biopsy as for DNA methylation profiling. The analysis focused on CpG 
sites that showed the same direction of effect in the n-DMR as in the single CpG site 
EWAS. We analysed gene expression data at 36 genes for 27 n-DMRs, where the n-
DMRs were either located in or were within 20kb of the gene (Table S3). Both DNA 
methylation and expression levels were adjusted for similar covariates and 
corresponding technical covariates and compared with Pearson correlation. At least 
one CpG site in 12 unique n-DMRs were shown to be correlated with the expression 
levels of 14 unique genes at nominal significance (p = 0.05, Table S3). This included 
one of the three CpG sites forming the third ranked n-DMR in KCNN4 (cg15977816, 
r = 0.19, p = 2.9 x 10-3). Strong n-DMRs that have more than one CpG site in the 
region correlated with one of more expression probes of the same gene include n-
DMRs at: MED11, C14orf50, FAM64A, KRT86, TTC15, and C6orf27.  
 
Naevus DNA methylation signature is enriched for melanoma associated DNA 
methylation changes 
Healthy tissue DNA methylomes can show risk-factor related signatures also 
found in malignant tissue (Noreen et al. 2014). Furthermore, tumour methylation 
patterns have been shown to derive from the continuum of maturation states that are 
reflected in normal developmental stages (Oakes et al. 2016). We therefore examined 
the DNA methylome data of melanomas to see whether our identified n-DMP 
signature was enriched within this malignant tissue epigenome.  
The most comprehensive melanoma DNA methylome study to date is a 
comparison between normal melanocytes from three donors and 27 metastatic 
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melanoma DNA samples using methylated-CpG island recovery assay sequencing 
(MIRA-Seq) by Jin et al. (Jin et al. 2015). They reported 3,113 regions that were 
hypermethylated in melanoma. Of these, 2,039 regions contained at least one CpG 
site profiled in our dataset and 13.4% (274 regions, containing 406 CpG sites) of 
these were identified as nominally significant with a positive association to total body 
naevus count. Within CGIs, which the MIRA-Seq technique targets, we observed an 
enrichment of hypermethylated nominally significant CpG sites (Fisher’s p = 6.33 x 
10-6). Another study, a genome-wide screen of promoter DNA methylation (24,103 
RefSeq promoters) between normal skin, naevi, and advanced stage melanoma 
identified four differentially methylated genes (Koga et al. 2009). At two of these 
genes, THBS1 and TNFRSF10D, we identified a positive association between total 
body naevus count and promoter CpG methylation, in line with their findings of 
increased DNA methylation in advanced stage melanoma. 
 
Impact of GWAS SNPs associated with total body naevus count or melanoma 
risk on skin DNA methylation in cis 
We next investigated the influence of genetic variants, previously associated 
in GWAS with naevus count or melanoma risk, on nearby DNA methylation levels in 
skin tissue for a subset of 283 individuals. We selected 4 SNPs previously associated 
with the number of cutaneous naevi (Falchi et al. 2009; Nan et al. 2011) and 23 SNPs 
associated with melanoma risk from the GWAS catalogue (Welter et al. 2014) that 
fall within 100 kb of CpG sites available in our dataset. Mixed linear models were 
performed to test for association accounting for family structure and results are 
presented at a threshold of p < 1.0 x 10-5. This is comparable to a genomewide cut-off 
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at FDR 1%, as reported previously (p < 8.6 x 10-4) where all DNA methylation was 
assessed within 100 kb of common genetic variants (Grundberg et al. 2013). 
Thirteen SNPs were significantly associated with DNA methylation changes 
in skin (p < 1 x 10-5, Table 3).  These included three of the four SNPs identified by 
GWAS to be associated with total body naevus count: rs2284063 in intron of PLA2G6 
(cg25457927, p = 3.5 x 10-38), rs3768080 in intron of NID1 (cg18765906, p = 6.4 x 
10-14), and rs738322 in another intron of PLA2G6 (cg25457927, p = 1.7 x 10-49). The 
results also included ten SNPs previously identified for melanoma risk reported at 
MC1R (2 SNPs), MX2, TERT/CLPTM1L, PLA2G6, CASP8, ACTRT3, ASIP, 
CDC91L1, and ARNT/SETDB1/LASS2ANXA9/MCL1/CTSK (Figure 4). Six of these 
CpG sites occurred in active promoters or enhancers in NHEK (derived from 
epidermal keratinocytes) (Ernst et al. 2011). None of the CpG sites associated with 
these SNPs were epigenome-wide statistically significant n-DMPs or within n-DMRs 
from our EWAS analysis. However, 9 naevus count CpG sites within these regions 
were associated with naevus count at nominally significance (p = 0.05), including the 
result at PLA2G6. 
The thirteen SNPs have not been previously reported as expression 
quantitative loci (eQTL) using the same skin biopsy expression data (Grundberg et al. 
2012). However, results from the Genotype-Tissue Expression Project (GTEx) 
(Consortium 2015) datasets show that eight of these SNPs are eQTLs in either skin 
tissue (sun or not sun exposed) and/or transformed fibroblasts. These GTEx eQTLs 
were associated with the expression of 16 genes in total, and at seven of these we 
identified DNA methylation variation associated with the same SNP: CASP8 
(rs1301693), MAFF, PLA2G6, TMEM184B, and BAIAP2L2 (rs2284063, rs738322, 
and rs6001027), SPATA33 (rs258322), MX2 (rs45430), and CDK10 (rs4785763).   
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DISCUSSION 
 
To our knowledge, this is the first study to explore epigenome-wide DNA 
methylation in the largest healthy human skin tissue dataset to date, in relation to 
number of naevi, the strongest risk factor of melanoma. This analysis adds an 
additional layer to our current understanding of the genomic biology of naevi 
development on top of that previously obtained via GWAS. We used normal skin 
biopsies of 322 healthy female twins and showed that these biopsies represent mostly 
homogenous dermis cells due to their distinct epigenetic signature. We identified 
DNA methylation variation associated with total body naevus count at, to our 
knowledge, previously unreported genes and also at known genes in naevi formation 
or melanoma, both at single CpGs as well as regions. These top-ranked results are 
significantly enriched for strong enhancers in NHEK cell lines as well as for CGI 
shores, regions identified as more dynamic and functional in both cancer (Irizarry et 
al. 2009) and stem cell reprogramming (Doi et al. 2009). Approximately half of the 
regional epigenetic changes tested also had corresponding gene expression differences 
in the same biopsy. Finally, we identified DNA methylation variation in cis associated 
with known GWAS SNPs for both naevi number and melanoma risk 
We identified many genomic loci that exhibited differential methylation 
associated with total body naevus count that were highly relevant to melanocyte 
biology and cancer. Among these is the n-DMR at CTC1, involved in telomere 
maintenance and associated with telomere length (Mangino et al. 2012). Telomere 
length has been positively associated with high naevus count and melanoma risk 
(Bataille et al. 2007), as well as via a genetic score analysis from 7 telomere length 
associated SNPs (Iles et al. 2014). This suggests that telomeres within healthy skin 
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may already be longer in high naevus count individuals as a similar rate of age-
dependent telomere length attrition has been shown between leukocytes and skin 
(Daniali et al. 2013), and supports previous work in melanoma biology . It may also 
explain why individuals with multiple atypical naevi are relatively protected against 
photo ageing, due to potential reduced skin senescence.  
An important molecular pathway highlighted, due to differential DNA 
methylation in RAF1, is the MAP/ERK pathway that includes BRAF. BRAF mutations 
are found in ~50% of all melanoma tumours and are of significant clinical utility as 
major therapeutic decisions are made according to the presence or absence of 
mutations in this gene (Flaherty et al. 2010). Somatic mutations in the oncogene 
RAF1 are remarkably rare in human cancers (Emuss et al. 2005), however, in BRAF 
negative melanomas, targeting RAF1 leads to apoptosis. Therefore the significant 
identification that this pathway is altered via DNA methylation could lead to the re-
evaluation of using mutational status alone in advanced melanoma treatment 
decisions (Heyn and Esteller 2012). 
 Another result of note is ARRDC1, part of the highly conserved cell signalling 
NOTCH pathway. This pathway is pivotal in cell-fate determination across many 
organ systems in embryogenesis and also tissue maintenance in adults. Expression of 
Notch1 is low or not detectable in melanocytes as well as naevi, however, higher 
expression is associated with their transformation to melanoma (Massi et al. 2006; 
Pinnix et al. 2009). ARRDC1 is necessary for Itch E3 ubiquitin ligase mediated 
NOTCH receptor degradation (Puca et al. 2013).  
 We also found that our naevi signature was enriched for DNA methylation 
changes previously identified in melanoma (Jin et al. 2015). This may indicate a 
priming or predisposition to melanoma of normal skin with more naevi. We then 
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investigated the effect of 26 unique genetic variants, previously associated by GWAS 
with naevus number (4 SNPs) or melanoma risk (23 SNPs), on DNA methylation 
within 100 kb (Falchi et al. 2009; Nan et al. 2011; Welter et al. 2014). Half of these 
SNPs were significantly associated with DNA methylation changes in skin tissue. For 
all three GWAS SNPs reported for PLA2G6, which is associated with both naevus 
numbers and melanoma, eQTLs have been reported in skin and/or transformed 
fibroblasts impacting on the expression of PLA2G6, MAFF, TMEM184B, and 
BAIAP2L2. All of these genes harboured SNP-associated DNA methylation variation 
in our study. This highlights the usefulness of integrating DNA methylation analysis 
with robust GWAS discoveries to identify functional pathways underlying strong 
genetic signals. Furthermore, we identified GWAS SNP-associated DNA methylation 
variation, not only in genes with known eQTLs, but also in novel genes.  
 Compared to other studies, our sample is much larger than previous skin DNA 
methylation studies (Roberson et al. 2012; Rodríguez et al. 2014; Vandiver et al. 
2015), and we have profiled only women, who are known to have different 
distribution of naevi on the body compared to men (Autier et al. 2004) as well as sex-
specific differences in DNA methylation (Singmann et al. 2015). Additionally, this 
study benefits from the extensive data for naevus counts collected by trained 
dermatology nurses of healthy individuals. In contrast to blood-based EWAS, this 
study also highlights the strength of investigating the phenotype-appropriate tissue to 
help understand biological pathways implicated in disease.  
 To conclude, this study based on skin biopsies of 322 healthy female 
Caucasians using DNA methylome, transcriptome, and GWAS data from the same 
individuals identified DNA methylation differences associated with number of naevi. 
We identified pathways and genes that add to our current understanding of the 
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biology of the number of naevi and the pathology of melanoma. These data open up 
avenues for future exploration in skin, not only why some individuals have higher 
numbers of naevi but how this phenotype contributes to melanoma risk. 
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MATERIALS AND METHODS 
 
Sample selection 
Detailed information regarding naevus count was obtained from twins 
registered with the TwinsUK Adult Twin Registry. The twins in this registry are not 
selected for diseases and were similar in means and ranges of quantitative phenotypes 
to an age-matched population in the UK (Andrew et al. 2001). Written informed 
consent from all subjects was obtained in accordance with Guy's & St Thomas' NHS 
Foundation Trust Ethics Committee (EC04/015 - 15-Mar-04). The selected 
individuals did not have a personal medical history of malignant melanoma or other 
skin cancers obtained through record linkage with the National Cancer Registry at the 
Office for National Statistics (ONS). The examination was performed by trained 
research nurses following a standardised and reproducible naevus count protocol as 
described previously (Bataille et al. 2000). Total body naevus count was the sum of 
all naevi > 2mm across 17 body sites.  
DNA methylation data profiled from skin tissue was available for 322 female 
twins with a mean age of 59 years old, including 25 MZ twin-pairs, 64 DZ twin-pairs, 
and 144 unrelated individuals of European descent. Punch biopsies (8 mm) were 
taken from a relatively photo-protected area adjacent and inferior to the umbilicus and 
were mechanically dissected for skin tissue removing the fat layer prior to freezing. 
Written informed consent from all study subjects was obtained and the procedures 
were in accordance with the ethical standards of the St. Thomas’ Research Ethics 
Committee (REC reference 07/H0802/84). The skin biopsy samples were obtained 
within 6.5 and 11.9 years after naevus count with a mean of 9.7 years (Figure S1).  
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Genome-wide DNA methylation profiles 
Genome-wide DNA methylation profiles were obtained from 326 bisulphite-
converted skin tissue DNA samples assayed by Illumina Infinium 
HumanMethylation450 BeadChip. DNA methylation levels were denoted as betas: 
the ratio of intensity signal from the methylated probes over the sum of intensity 
signals from both unmethylated and methylated probes. Multiple measurements of 
analytical quality were applied. Probes were removed for the main analyses that: 
failed detection in at least one sample or had a bead count less than 3 in more than 1% 
of the samples (n=18,208), had a 50 bp probe sequence that aligned to multiple 
locations in the genome (n=17,764), harboured common genetic variants (MAF ≥ 1%) 
within 10 bp on the probe at the interrogated CpG site (15,827), or contained variants 
at any MAF within 10 bp at the interrogated CpG site (11,236), and were located on 
the sex chromosomes (n=11,650). Probes with genetic variants within the 50 bp of the 
CpG, but not within 10 bp were not excluded for GWAS SNP analyses but were 
highlighted as such in the figures and accompanying text. 
Individuals were verified using the 57 autosomal SNP probes included as 
control probes on the BeadChip. Overall intensity signal as well as bisulphite 
conversion efficiency were assessed and the data was inspected visually for outliers 
using beta density plots, boxplots, and imprinted regions (using the R package 
wateRmelon (Schalkwyk et al. 2013)). Four individual samples were excluded based 
on low mean intensity signals. The remaining 322 samples were normalised using the 
BMIQ method to correct for probe type bias (Teschendorff et al. 2013). Principal 
component analysis (PCA) was performed on BMIQ normalised beta values that were 
standardised (N(0,1)) at each probe. The first three principle components (PCs), 
which when combined explain 36% of the total variance, were assessed for 
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associations with possible confounders for DNA methylation data including 
BeadChip, position on the BeadChip, age, smoking status, body mass index (BMI), 
and bisulphite conversion efficiency. Strongly significant associations (p < 1 x 10-20) 
were identified with BeadChip and bisulphite conversion efficiency.  
 
Gene expression profiles 
Gene expression profiles were obtained of the same skin tissue biopsies which 
were profiled for DNA methylation for 248 individuals from the MuTHER project 
(Multiple Tissue Human Expression Resource) as previously described (Grundberg et 
al. 2012). In short, punch biopsies (8mm) were taken from a photo-protected area 
adjacent and inferior to the umbilicus of which skin tissue was dissected. RNA was 
extracted and expression profiling was performed using Illumina Human HT-12 V3 
BeadChips. Probes with less than three beads present were excluded and log2-
transformed expression signals were normalized separately per tissue, with quantile 
normalization of the replicates of each individual followed by quantile normalization 
across all individuals.  
 
Genotypes 
Genotype data of 283 individuals were available from the TwinsUK dataset as 
previously described (Small et al. 2011), genotyped using a combination of Illumina 
HumanHap300, HumanHap610Q, 1M-Duo, or 1.2M-Duo custom arrays. Imputation 
was done based on 1000 Genomes data phase 3. Quality control measures included 
minimum genotyping rate (>95 %), Hardy–Weinberg equilibrium (p > 10−6), 
minimum MAF (>1%) and imputation quality score >0.5 for GWAS catalogue SNPs. 
This subset of individuals included only individuals of Caucasian ancestry. 
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Statistical analysis 
DMPs associated with total body naevus count were identified using a linear 
mixed effects model fitted on the normalized beta values per probe (N(0,1)) with total 
body naevus count, age, BMI, smoking, bead chip, position on the bead chip, and 
bisulphite conversion efficiency as fixed effects, and family and zygosity as random 
effects. This model was compared to a null model that excluded total body naevus 
count by ANOVA. Results were considered genome-wide significant if they 
surpassed a FDR threshold of 5% and considered suggestive when surpassing an FDR 
of 10%, estimated using ‘qvalue’ in R.  
Naevus count DMPs were tested for association with age using a linear mixed 
effects model fitted on the normalized beta values per probe (N(0,1)) with age, BMI, 
smoking status, BeadChip, position on the BeadChip, and bisulphite conversion 
efficiency as fixed effects, and family and zygosity as random effects. This was 
compared to a null model without age by ANOVA to test for significance. 
 Small differentially methylated regions (DMRs) associated with naevus count 
were identified using R package ‘Bumphunter’ (Jaffe et al. 2012). Regions required at 
least three consecutive probes with a maximum gap of 500 bp between each probe. 
DNA methylation was adjusted for covariates described previously for DMP analysis 
before using Bumphunter. Naevus count DMRs were considered with a p-value < 
0.01 estimated based on 1000 permutations.  
 Gene expression analysis of the top-ranked DMRs was performed in a sample 
of 248 individuals using the same skin tissue biopsy used for DNA methylation 
profiling. A linear mixed model was fitted on the expression data with age, BMI, 
smoking status, batch, and concentration (fixed effects) and family and zygosity 
(random effects) as well as the linear mixed model fitted for DNA methylation data 
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described previously for n-DMP analysis. The residuals from both models were 
compared with Pearson correlation.   
Genotype variation analyses using GWAS SNPs were performed in a sample 
of 283 individuals using genome-wide efficient mixed model association (GEMMA) 
to account for family structure present in the data and adjusted DNA methylation 
levels for fixed covariates used in the n-DMP analysis (age, BMI, smoking status, 
BeadChip, position on the BeadChip, and bisulphite conversion efficiency).  
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Table 1. Most associated naevus differential methylation positions (nDMPs) 
Rank CpG Position (hg19) Associated 
gene 
Location 
CpG 
island 
Beta St. Error P value FDR 
1 cg06244240 chr17: 81058948 - - Shore 0.0052 0.0009 5.52 x 10-8  5% 
2 cg06123942 chr15: 45722795 C15orf48 5'UTR Island -0.0074 0.0014 2.20 x 10-7 5% 
3 cg25384157 chr9: 140499131 ARRDC1 TSS1500 Shore 0.0063 0.0012 3.06 x 10-7 5% 
4 cg11297934 chr3:12705868 RAF1 TSS200 Island -0.0046 0.0009 1.16 x 10-6 10% 
5 cg14762973 chr2:187714067 ZSWIM2 TSS200 Island 0.0069 0.0014 1.49 x 10-6 10% 
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Table 2. Most associated naevus differential methylation regions (nDMRs) 
 
Rank Position (hg 19) Associated 
Gene 
Location CpG 
Island 
Number 
of CpG 
sites 
DNA 
methylatio
n  
P value Overview direction 
CpG sites 
1 chr9:140499132-
140500813 
ARRDC1 TSS1500-
Body 
Island 7 + 2.5 x 10-5 + + - - - + + 
2 chr10:14647154-
14647530 
FAM107B Body Shore 3 + 2.5 x 10-4 + + + 
3 chr19:44285297-
44285568 
KCNN4 TSS200-
1stExon 
- 3 + 2.9 x 10-4 + + + 
4 chr17:8129997-
8130356 
CTC1 3'UTR Shelf 3 - 6.3 x 10-4 - - - 
5 chr15:26915414-
26915752 
GABRB3 Body Island 3 - 8.3 x 10-4 - - - 
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Table 3. Strongest CpG association per GWAS SNP. 
Trait  rs Position (hg19) Reported 
Genes 
cpg beta P value Associated 
Gene 
Location CpG 
Islan
d 
Distanc
e to 
SNP 
(kb) 
Melanoma rs401681 chr5:1322087 TERT, 
CLPTM1L 
cg06550200 0.783 2.6 x 10-
50
  
CLPTM1L Body - -3.5 
Cutaneous nevi rs738322 chr22:38569006 PLA2G6 cg25457927 0.851 1.7 x 10-
49
 
- - Shelf -26.4 
Melanoma rs45430 chr21:42746081 MX2 cg22778903 -0.711 1.9 x 10-
42
 
MX2 5'UTR - 4.4 
Melanoma rs6001027 chr22:38545619 PLA2G6 cg25457927 0.843 1.3 x 10-
38
 
- - Shelf -49.8 
Cutaneous nevi 
& Melanoma 
rs2284063 chr22:38544298 PLA2G6 cg25457927 0.834 3.5 x 10-
38
 
- - Shelf -51.1 
Melanoma rs7412746 chr1:150860471 ARNT, 
SETDB1, 
LASS2, 
ANXA9, 
cg15448220 0.662 1.4 x 10-
32
 
SETDB1 TSS1500 Shore -37.4 
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MCL1, 
CTSK 
Melanoma (2) rs258322 chr16:89755903 MC1R cg05714116 -0.728 5.5 x 10-
14
 
CDK10 TSS1500 Shore 3.3 
Cutaneous nevi rs3768080 chr1:236179869 NID1 cg18765906 -0.374 6.4 x 10-
14
 
NID1 Body - 4.5 
Melanoma rs4785763 chr16:90066936 MC1R cg08547343 -0.346 1.0 x 10-9 CENPBD1;
AFG3L1 
5'UTR; 
TSS200 
Island 28.1 
Melanoma rs910873 chr20:33171772 CDC91L1 cg01901788 -0.441 1.8 x 10-6 MAP1LC3
A 
TSS1500 Shore 25.9 
Melanoma rs1309702
8 
chr3:169464942 ACTRT3 cg27020690 -0.289 2.0 x 10-6 - - Island -17.4 
Melanoma rs1301696
3 
chr2:202162811 CASP8 cg24599065 -0.230 2.1 x 10-6 CASP10 3'UTR - 69.0 
Melanoma rs228437 chr6:134898456 ASIP cg24504307 -0.355 9.2 x 10-6 - - - -64.7 
Melanoma rs3219090 chr1:226564691 PARP1 cg18764804 0.240 6.2 x 10-4 PARP1 TSS1500 Shore -32.0 
Melanoma rs1031925 chr3:51379274 DOCK3 cg09456445 -0.315 8.5 x 10-4 DOCK3 3'UTR Shore -41.1 
Melanoma rs1722784 chr1:150961869 ANXA9 cg07479786 0.261 8.9 x 10-4 ANXA9 3'UTR - -6.0 
Melanoma rs1695300 chr16:54114824 FTO cg01083598 -0.169 7.2 x 10-3 - - Island -41.2 
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2 
Melanoma rs35390 chr5:33955326 SLC45A2 cg01990593 0.689 8.8 x 10-3 ADAMTS1
2 
Body Shore 65.0 
Melanoma rs1801516 chr11:10817546
2 
ATM cg08954307 -0.249 9.8 x 10-3 ATM Body - -59.3 
Cutaneous nevi rs4636294 chr9:21747803 MTAP cg03724238 -0.128 0.013 - - Island 51.1 
Melanoma rs4698934 chr4:106139387 TET2 cg08530497 -0.195 0.037 TET2 Body - -15.9 
Melanoma rs1847134 chr11:89005253 TYR cg25941151 -0.153 0.041 TYR TSS200 - 94.3 
Melanoma (2) rs7023329 chr9:21816528 CDKN2A cg14548963 0.118 0.068 MTAP Body - 3.6 
Melanoma (2) rs1393350 chr11:89011046 TYR cg03508346 -0.118 0.142 NOX4 3'UTR - -48.8 
Melanoma rs1711946
1 
chr10:10751635
2 
NR cg18758405 -0.290 0.333 - - - 65.0 
Melanoma rs1889497 chr6:65432283 EYS cg11999886 -0.026 0.760 EYS Body - 90.8 
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FIGURE LEGENDS 
 
Figure 1. Global DNA methylation profiles and skin tissue specificity. 
First two principal components coloured by layer specificity; red for dermal tissue, 
blue for epidermal tissue, and green for our data (see legend). 
 
Figure 2. Naevus count epigenome-wide results in 322 female individuals.  
[a] Manhattan plot of the epigenome-wide association results in 322 female 
individuals, where each point represents the observed –log10 p value at a CpG-site. [b] 
Panel plot depicting direction of association at the three top-ranked signals for 
cg06244240 (left), cg06123942 (middle), and cg25384157 (right). Results are plotted 
using normalised unadjusted beta values per individual. The lines represent the linear 
correlation between DNA methylation and total body naevus count. [c] Heatmap of 
top 48 ranked n-DMPs coloured by –log10 p values of age association and naevus 
association. 
 
Figure 3. Location of two top ranked n-DMRs in the human genome. 
Figures obtained from UCSC Genome browser, displaying position in the genome 
(hg19), CpG sites from HumanMethylation450 BeadChip, n-DMR (in light blue), 
RefSeq genes, CpG island, transcription factor ChIP data, DNase-I sensitivity sites, 
and ChromHMM genomic segmentation. [a] At ARRDC1. [b] At CTC1.  
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 32 
Figure 4. GWAS SNPs for naevus count or melanoma risk vs DNA methylation 
in skin tissue in cis. 
Regional plot of 100kb flanking regions around the GWAS SNP of interest denoted as 
striped black line. Each point is a CpG site with its p value on the y-axis. The plots 
are annotated with a gene track from LocusZoom. Each point is coloured according to 
occurrence of genetic variants on the probe sequence (see legend) [A] rs738322 
identified for cutaneous naevi [B] rs3768080 identified for cutaneous naevi [C] 
rs45430 identified for melanoma risk [D] rs401681 identified for melanoma risk. 
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